Peptide Lab

CJC-1295 (No DAC)

$39.99

In stock

CJC-1295 is an investigational synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), a hormone that signals the pituitary gland to release growth hormone. Research has examined its ability to increase growth hormone and insulin-like growth factor 1 (IGF-1), a hormone involved in growth and tissue metabolism.

SKURC-ST-CJC1295N-5MG
ManufacturerStrandix Peptides
FormLyophilized Powder
Strength5 mg
Size3 mL Vial
Reported ResultSee matching batch report
StockIn stock
Documentation StatusClient-supplied report available

Product Description

CJC-1295 is an investigational synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), a hormone that signals the pituitary gland to release growth hormone. Research has examined its ability to increase growth hormone and insulin-like growth factor 1 (IGF-1), a hormone involved in growth and tissue metabolism.

What research has shown for CJC-1295 with DAC:

Increased growth hormone: Two randomized, placebo-controlled trials in healthy adults found dose-dependent increases in average growth hormone levels lasting at least six days after a single administration.

Increased IGF-1: The same trials reported elevated IGF-1 levels lasting approximately 9–11 days after a single administration.

Preserved growth hormone pulses: A separate human study found that growth hormone continued to be released in pulses while baseline and average levels increased. Pulse frequency and magnitude were not significantly changed.

Storage and handling: Keep unopened lyophilized material sealed, protected from light and moisture, and stored according to the manufacturer label and current COA. Product-specific stability after reconstitution must be supported by manufacturer data; avoid publishing a universal reconstituted shelf life.

For laboratory research use only. Not for human or animal consumption.
Lab analysis

Third-party testing status.

Batch / LotReported ResultTestedPartnerStatusDocument
CND5/2025-12-18-B99.295%; 99.307%Jan 5, 2026JanoshikClient-supplied reportView COA